key: cord-0790241-a3tow8wa
authors: Novikov, Mikhail; Hasanpourghadi, Mohadeseh; Ambrose, Robert; Chekaoui, Arezki; Newman, Dakota; Giles-Davis, Wynetta; Xiang, Zhiquan; Zhou, Xiang Yang; Ertl, Hildegund CJ
title: Pre-clinical testing of two serologically distinct chimpanzee-origin adenovirus vectors expressing spike of SARS-CoV-2
date: 2022-02-24
journal: bioRxiv
DOI: 10.1101/2022.02.23.481620
sha: 9dd93845d3ccd7be42d0068f9ded0990d6391bc7
doc_id: 790241
cord_uid: a3tow8wa

Two serologically distinct chimpanzee-origin, replication-defective adenovirus (AdC) vectors expressing the spike (S) protein of an early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolate were generated and tested for induction of antibodies in young and aged mice. Both vectors induced S protein-specific antibodies including neutralizing antibodies. Levels of antibodies increased after a boost. The effectiveness of the boost depended on vector dose and timing between the two immunizations. Using two heterologous AdC vectors was more effective than vaccinating with the same vector repeatedly. Antibodies partially crossreacted between different S protein variants. Cross-reactivity increased after booster immunization with vectors carrying the same S gene, expression of two different S proteins by the AdC vectors used for the prime and the boost did not selectively increase responses against the variants.

The global COVID-19 pandemic caused by SARS-CoV-2 killed millions of people worldwide.

After the virus was first identified and sequenced at the beginning of 2020 1,2 vaccines were developed rapidly and entered clinical trials a few months later and within less than one year after onset of the pandemic several gained emergency approval. Those that became first available in the US or Europe are based on mRNA vaccines 3, 4 or replication-defective adenovirus (Ad) vectors derived from human (HAdV) 5,6 or chimpanzee 7 serotypes. Additionally inactivated SARS-CoV-2 vaccines were generated and used in South America, Asia, and Africa. 8, 9 All recombinant COVID-19 vaccines used for mass vaccination thus far express the S protein of an early isolate. The S protein binds to the viral receptor, i.e., angiotensin-converting enzyme 2 (ACE2), and is the target for virus neutralizing antibodies (VNAs), 10 which were shown to protect against infection. 11 COVID-19 vaccines based on two doses of mRNA are highly efficacious and protect >90% of vaccine recipients. 11, 12 The efficacy of the Ad vector vaccines varies; the one dose J&J vaccine shows 67% protection against disease, 13 the chimpanzee-derived Ad (AdC) vaccine from AstraZeneca that uses the same vector twice has an efficacy of 76% 14 while the two dose Sputnik V vaccine that primes with one human serotype Ad vector and then boosts with a serologically distinct Ad vector is as efficacious as the mRNA vaccines. 8 Although the SARS-CoV-2 vaccines are highly efficacious, they primarily prevent disease rather than infection and protection declines after a few months. [15] [16] [17] [18] [19] [20] A boost at 6 months after the initial immunization with one of the most commonly used vaccine prototype, i.e., the mRNA vaccines, increases VNA titers albeit only temporarily potentially necessitating another boost as soon as 4 months later. 21 Although an additional boost was shown to restore protection, antibody titers failed to exceed those after the 3 rd boost. 22 Confounding the problem of short-live immunity after COVID-19 vaccination has been the emergence of more transmissible viral variants that partially escape the vaccine-induced immune responses including those after 4 doses of the mRNA vaccines. [22] [23] [24] [25] Limited pre-clinical studies were conducted with the COVID vaccines to optimize immune responses regarding potency and longevity by testing different vaccine doses, varying timing between the prime and the boost or systematically exploring the use of heterologous vaccine platforms. The short-lived efficacy of the most used COVID-19 vaccines is of concern; it is not feasible to vaccinate the human population every 4 to 6 months. Additional studies to develop second generation vaccines or vaccine regimens, which induce more sustained protective immunity are needed.

Here we describe pre-clinical results with two serologically distinct AdC vectors expressing the S protein of an early SARS-CoV-2 isolate. Our results show that the vaccines induce S proteinspecific antibodies including VNAs in young and aged mice. Antibody responses increase after a boost and are then maintained at stable levels for at least 5 months. The magnitude of the booster response depends on vaccine dose and interval between the two immunizations and is enhanced by using heterologous vectors. VNAs generated by a single vaccine dose show limited responses to the S protein of viral variants; cross-reactivity increases after a boost.

Vaccinating mice sequentially with two AdC vectors expressing either the S protein of the early SARS-CoV-2 isolate, or a version in which the receptor binding domain (RBD) had been mutated to resemble the South African variant followed by a boost with an AdC vector expressing the early S protein only marginally improves cross-reactivity of VNAs to additional viral variants.

We developed E1-deleted AdC6 (SAdV-23) and AdC7 (SAdV-24) vectors expressing the S protein of an early SARS-CoV-2 isolate from Sweden called SARS-CoV-2/human/SWE/01/2020 (AdC-SSWE, GenBank number: QIC53204). In addition, we generated an AdC6 vector expressing the same S protein in which the RBD sequence was modified to incorporate the E484K and N501Y mutations of the B1.351 South African variant (AdC6-SSWE/B1.351). Vectors were produced with the help of available molecular Ad clones 26 and upon expansion, purification, titration and passing quality control assays they were tested for protein expression upon transfection of HEK-293 cells. As shown in Suppl. Fig. 1A both types of AdC vectors express a protein of the expected size that binds the anti-S protein antibody.

To allow for testing of VNAs we developed several green fluorescent protein (GFP)-expressing VSV vectors that were pseudotyped with S protein of SARS-CoV2 (VSV-S). 27 One carries the same S protein as the vaccine vectors (VSV-SSWE). In a second the SSWE sequence was To establish a neutralization assay with the VSV-S vectors, we tested 3 different cell lines including the commonly used VeroE6 cell line but decided on baby hamster kidney (BHK)-21/WI-2 cells, as they gave more consistent results. BHK-21/WI-2 cells express the ACE2 receptors that is used by SARS-CoV2 for cell entry as was shown by immunofluorescent staining and flow cytometry (Suppl. Fig. 1B ). VSV-SSWE virus transfection of BHK-21/WI-2 cells is prevented by human antibodies from individuals, who experienced a SARS-CoV-2 infection but not by antibodies from sera of noninfected human controls (Suppl. Fig. 1C ). It is also neutralized by sera from S protein-immune but not naïve mice (Suppl. Fig. 1D ).

Groups of outbread ICR mice (5/group) were immunized with 10 9 , 10 10 , or 5 x 10 10 virus particles (vp) of the AdC6-SSWE and AdC7-SSWE vectors. Mice that received the lowest vector dose were boosted 4 weeks after the prime; the other mice were boosted 6 weeks after the prime. All mice were boosted with heterologous AdC vectors given at the same doses that had been used for priming. Mice were bled 2 and or 4 weeks after the prime and 2 weeks after the boost. Mice that received the 1 x 10 10 vp doses were kept for an additional 5 months and bled at 3 and 5 months after the boost (19 and 27 weeks after the prime) to determine duration of antibody responses (Fig. 1A) . Sera from individual mice were tested by an enzyme-linked immunosorbance assay (ELISA) on a mixture of commercially available S1 and S2 proteins of SARS-CoV-2. By 2 weeks after the prime mice in the high dose group developed detectable S protein-specific antibodies while by 4 weeks all animals but for one mouse in the low dose AdC6-SSWE group seroconverted (Fig.1B) . Response magnitude was dose dependant.

Responses significantly increased by 2 weeks after the boost in most groups ( Fig 1C) .

Antibodies as tested for the 10 10 vp vaccine groups were maintained at stable levels for at least 5 months after the boost. Antibody isotypes were tested using pooled sera from different time points at a 1:100 dilution. Responses were dominated by antibodies of IgG2 isotypes indicative of the T helper cell type 1 response (Fig. 1D ).

Some sera from the same mice were tested for neutralization of SARS-CoV-2 virus (Figure 2A ). Sera from mice immunized with 1 ´ 10 10 or 5 ´ 10 10 vp of the AdC vectors were analyzed by a surrogate neutralization assay that tests sera for inhibition of binding of human ACE2 to S protein's RBD 28 (Fig. 2B ). All mice developed RBD-specific antibodies by week 10, which were maintained without significant declines through week 27.

Sera were in addition tested in a neutralization assay with the VSV-SSWE vector. After the boost all mice but for one in the low dose AdC6-SSWE group developed VNAs with geometric mean (GM) titers ranging from 1:80 in the low dose AdC6-SSWE prime group to 1:840 in the intermediate dose AdC7-SSWE prime group (Fig. 2C,D) .

We used different intervals between the prime and boost and explored the sequential use of homologous vs. heterologous AdC-SSWE vectors. For these experiments 3 groups of 5 ICR mice were tested (Fig. 3A) . The 1 st group was primed with 2 ´ 10 10 vp of AdC6-S SWE. Mice were boosted 2 weeks later with the same dose of AdC7-SSWE. The 2 nd group received the same vaccines at the same dose and in the same order but the boost was delayed till week 8. The 3 rd group was primed with 2 ´ 10 10 vp of AdC7-SSWE and then boosted 8 weeks later with the same AdC7-SSWE vector used at the same dose. Mice were bled periodically and antibody titers to S protein were determined by ELISA. As shown in Fig 

We conducted an experiment in young (6-8 weeks of age, n = 5) and aged (1-2 years of age, n = 7) C57Bl/6 mice. Mice were immunized with a low dose of 2 ´ 10 9 vp of the AdC7-SSWE vector and boosted 6 weeks later with 2 ´ 10 9 vp of the AdC6-SSWE vector (Fig. 4A ). Naive young (n = 3) and aged (n = 2) mice were used as controls. Sera of individual mice were tested 2 weeks after the boost by an ELISA (Fig. 4B ) and a VSV-SSWE virus neutralization assay (Fig. 4C ).

Antibody responses tested by the S protein ELISA or the VNA assay tended to be higher in young mice although this did not to reach significance. All of the young mice developed VNAs while 2 out of 7 aged mice failed to respond.

To test if the AdC-S vaccines induce antibodies that cross-neutralize viral variants we selected sera from ICR mice that had been immunized once or twice with AdC-SSWE vectors and had shown positive neutralizition of the VSV-SSWE vectors, and tested them for cross-reactivity with VSV vectors pseudotyped with different versions of S protein carrying RBD mutations found in viral variants of concern. A total of 61 or 22 sera harvested after priming ( Protective immunity induced by mRNA vaccination against COVID-19 is short lived. [16] [17] [18] [19] [20] [21] 35 As this was also observed in a previous trial testing an mRNA vaccine against rabies virus 36 the rapid waning of protective immunity most likely relates to the vaccine platform rather than the disease application. The short-lived duration of mRNA vaccine-induced protection contrasts with that achieved by other viral vaccines based on attenuated viruses such as the those against smallpox or yellow fever virus, subunit vaccines such as the hepatitis B virus vaccine, or virus like particle vaccines such as the HPV vaccines, which in general provide protection for at least 5-10 years. [37] [38] [39] The lifespan of an antibody secreting plasma cell and the magnitude of the memory B cell response is dictated by several factors including strength of B cell receptor signaling, which in part is driven by receptor cross-linking, presence of T help and the type of the inflammatory milieu that is elicited by a pathogen or a vaccine. 40 vaccines but not to the Sputnik V vaccine. 50, 51 One clear disadvantage of Ad vector vaccines is that immune responses to the transgene product are dampened by pre-existing VNAs to the vaccine carrier. [52] [53] [54] Such antibodies can be induced by natural infections and consequently prevalence rates of VNAs to HAdV5 are globally high while VNAs to HAdV26 are common in humans residing in Africa. 52 A single immunization with an Ad vector vaccine likely induces more modest levels of Ad-specific VNAs due to lower antigenic loads although repeated vaccination with the same Ad vectors is expected to gradually increase titers so that they will reach those seen after a natural infection. One clinical study with an HAdV5-based COVID vaccine from CanSino Biologicals monitored induction of Ad vectorspecific VNAs and, as expected, showed that they increased after vaccination. The same study reported an albeit insignificant inverse correlation between VNA titers to the HAdV5 vector and COVID S protein-specific antibody responses. 55 VNAs to the vaccine vectors will likely pose limitations to repeated booster immunization using the same Ad vector by not only reducing, but also, as we reported previously, modifying transgene product-specific immune responses. 56 To avoid interference by Ad vector-specific VNAs, we developed a vaccine regimen composed of two serologically distinct E1-deleted AdC vectors. We selected AdC vectors as pre-existing VNAs to these chimpanzee viruses are rare in humans and individuals who have VNAs in general have low titers. 44 We developed two serologically distinct AdC vectors to prevent blunting of booster immunizations by VNAs induced by the AdC vector used for priming. The two AdC vectors express the S protein of an isolate from Sweden, which is identical to that of the original Wuhan virus. We did not codon-optimize the S sequence, nor did we incorporate the K986P and V987P stabilizing mutations into the S2 sequence which both were used for the S gene expressed by the RNA vaccines, 57 mutations of the S1/S2 furin cleavage site which, in addition to the stabilizing mutations, were incorporated into the S gene carried by the J&J COVID-19 vaccine, 58 or AstraZeneca's engineered leader sequence. 59 Phase III trial results of the different Ad vector vaccines fail to indicate that any of these modifications have a major impact on vaccine efficacy.

In our study, as expected, the magnitude of S protein-specific antibody responses after a single immunization increased with higher vaccine doses. This pattern changed after boosting, where the highest dose performed poorly. Timing of boosting seems to affect the magnitude of the recall response as was reported for both the AstraZeneca and J&J vaccines. 60, 61 There were no significant differences between responses induced by the AdC6-S or AdC7-S vectors although after two immunizations the AdC7/AdC6 regimen tended to outperform the AdC6/AdC7 regimen. In our study a short interval of 2 weeks between two vaccine doses resulted only in marginal increases in antibody titers as compared to a longer interval of 8 weeks. We assume, but this must be investigated in more depth, that the optimal interval between repeated immunizations may depend on the vector dose used for priming with lower doses allowing for shorter intervals and may well exceed 8 weeks for higher doses. 62 Repeated use of the same vector also reduces the effectiveness of the booster immunization, which is likely caused by Ad vector specific VNAs, which reduce transduction rates and thereby expression levels of the transgene product. Again, we assume that the inhibitory effect of Ad vector-specific VNAs will depend on pre-existing memory and vector dose, which both affect the magnitude of the response, as well as on timing of the booster immunization with longer intervals being advantageous by allowing for a decline in Ad vector-specific antibody titers. Alternatively, inhibition by Ad vector specific VNAs can be circumvented by using heterologous vectors for prime boosting such as in the Sputnik V vaccine or our pre-clinical vaccines or by changing vaccine platforms. In our study the importance of a boost was stressed by the relative lack of cross-reactivity of antibodies generated after a single immunization against S proteins with RBD mutations present in key variants such as the delta variant.

It is unlikely that SARS-CoV-2 will ever be eradicated. This will necessitate periodic booster immunizations and additional investments into 2 nd generation vaccines that achieve more sustained immunity and preferentially not only protection against symptomatic disease but also against infections. Booster immunizations with available Ad vector vaccine will over time become less and less effective due to the induction of vector neutralizing antibodies. This could be addressed using alterative Ad serotypes such as those described here. VNA assay with VSV-S. VSV-S vectors was initially titrated on BHK-21/WI-2 cells. The cells were diluted to 4 ´ 10 5 cells/ml in DMEM with 5%FBS and 5 µl were of the cell dilution was added to each wells of Terasaki plates. The next day serial dilutions of VSV-S vectors were added to duplicate wells. The following day numbers of fluorescent cells/well were counted with a fluorescent microscope (Suppl. Fig. 1D ). For the neutralization assay a dose of VSV that infected ~40-60 cells/well was selected.

For the neutralization assay, BHK-21/WI-2 cells were plated into Terasaki plate wells as described above. The following day, sera were serially diluted in DMEM with 5% FBS and then incubated with VSV-S diluted in the same medium for 90 min at room temperature under gentle agitation starting with a serum dilution of 1 in 40 or 1 in 100. 5µl aliquots of the mixtures were transferred onto BHK-21/WI-2 within the Terasaki plate wells. Each serum dilution was tested in duplicates, an additional 4-6 wells were treated with VSV-S that had been incubated with medium rather than serum. Plates were incubated for 24-48 hr and then numbers of fluorescent cells were counted. Titers were set as the last serum dilution reduced numbers of greenfluorescent cells by at least 50%.

The COV-PosSet-S from RayBiotech (Peachtree Corners, GA), which contains 20 human samples from individuals that recovered from COVID-19 or from uninfected individuals was used to validate the neutralization assay.

ACE binding inhibition assay. Sera were tested for inhibition of ACE binding to the RBD of S by the Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit from Acro Biosystems (Newark, DE) following the manufacturer's instructions. A positive standard with a known concentration provided by the kit was used to extrapolated anti-S antibody concentrations in µg in the mouse sera.

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Interim results of a Phase 1-2a Trial of Ad26.COV2.S COVID-19 Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Double-blind, randomized, placebo-controlled Phase III Clinical Trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Protection of BNT162b2 vaccine booster against Covid-19 in Israel

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance -VISION Network

4th dose COVID mRNA vaccines' immunogenicity & efficacy against Omicron VOC. Preprint. Infectious Diseases (except HIV/AIDS). Epub ahead of print

SARS-CoV-2 variants of concern are emerging in India

A highly transmissible SARS-CoV-2 variant

Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies

An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virusbased assay

A simple protein-based surrogate neutralization assay for SARS-CoV-2

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Effects of a SARS-associated coronavirus vaccine in monkeys

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques

Waning 2-Dose and 3-Dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance -VISION Network, 10 States

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years

A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries

Immunity from Smallpox Vaccine Persists for Decades: A Longitudinal Study

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity: Long-term antibody production

Germinal centre-driven maturation of B cell response to mRNA vaccination

mRNA COVID-19 vaccines and long-lived plasma cells: a complicated relationship

Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines

Protection of non-human primates against rabies with an adenovirus recombinant vaccine

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices -United States

COVID-19 vaccine and the cold chain implications for global adoption

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination

Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae

Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?

The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1

Neutralizing antibodies against SARS-CoV-2, anti-Ad5 antibodies, and reactogenicity in response to Ad5-nCoV (CanSino Biologics) vaccine in individuals with and without prior SARS-CoV-2

Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

CNBC J&J covid vaccine booster shot is 94 percent effective when given at two months Available from

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans

HCJE holds equity in Virion Therapeutics. She serves as a Consultant to several Gene Therapy companies and the Gamaleya Institute.